A single plasmid vector system for packaging recombinant human adenovirus type 4. The vector system contains an E3 region-deleted human adenovirus type 4 (HAdV-4 or Ad4) genome, a vector sequence for amplifying plasmids in bacteria, a pBR322 replication origin, a kanamycin resistance gene, and a replication control sequence; and an exogenous gene embedding site is located behind a packaging signal of the human adenovirus type 4 and in front of an E1 region. The present invention further provides a method for packaging the recombinant human adenovirus type 4 by the single plasmid vector system and an application in vaccine and drug preparation. The vector system can be used for rapidly and efficiently preparing a human adenovirus type 4 vector recombinant virus for stably expressing an exogenous gene, and has a good application prospect in the fields of preparation of a diagnostic kit, a vaccine, a gene therapy kit and/or a tumor therapy drug, etc.

The present invention relates to a cell line, use of the cell line and a method for producing infectious viral particles using said cell line.

Introduction of DNA fragments into eukaryotic cells exposes them to cellular enzymes, such DNases that have the ability to destroy these DNA fragments and thus reduce the function. The invention provides means and methods reducing the enzymatic destruction of linear DNA fragments transfected into cells. To this purpose, expression constructs are designed that carry genes for proteins that bind to DNA fragments and prevent the enzymatic destruction of the linear DNA fragments. The use of these genes and expression vectors in modifying packaging cells for the enhanced production of viral gene therapy vectors and methods of making these packaging cells are provided.

The present invention relates to a helper plasmid-based gutless adenovirus (GLAd) production system, a gutless adenovirus production method using same, a gutless adenovirus produced using same, and a use of gutless adenovirus produced using same.

The present disclosure provides a recombinant adenovirus for expressing African swine fever virus (ASFV) EP153R-EP402R protein and a construction method thereof, and belongs to the technical field of genetic engineering. In the present disclosure, a recombinant adenovirus vector pAD-CMV-EGFP-EP153R-EP402R is obtained through a series of intermediate processes using a recombinant adenovirus shuttle vector pENTRE-EGFP-TOPO; the recombinant adenovirus vector is linearized to transfect AD293 cells, a recombinant virus is screened according to cytopathy formed by adenovirus infection, an adenovirus packaging process is achieved, and the recombinant adenovirus for expressing ASFV EP153R-EP402R protein is obtained, laying a foundation for the construction of a recombinant adenovirus vaccine for expressing the ASFV EP153R-EP402R protein.

The embodiments disclosed herein relate to the construction of fully-deleted Adenovirus-based gene delivery vectors packaged without helper Adenovirus, and more particularly to their use in gene therapy for gene and protein expression, vaccine development, and immunosuppressive therapy for allogeneic transplantation. In an embodiment, a method for propagating an adenoviral vector includes (a) providing an Adenovirus packaging cell line; (b) transfecting a fully-deleted Adenoviral vector construct into the cell line; and optionally (c) transfecting a packaging construct into the cell line, wherein the fully-deleted Adenoviral vector construct and optionally the packaging construct can transfect the Adenovirus packaging cell line resulting in the encapsidation of a fully-deleted Adenoviral vector independent of helper Adenovirus. In an embodiment, a target cell is transduced with the encapsidated fully-deleted Adenoviral vector for treating a condition, disease or a disorder.

A fast and accurate three-plasmid oncolytic adenovirus recombinant packaging system Ad5MixPlus and an application thereof are provided. The system is composed of three adenovirus recombinant plasmids. The core technology of the system is that two sets of different site recombination sequences are skillfully loaded on a first 5-type adenovirus right arm backbone plasmid large vector, then two small shuttle plasmids respectively provide a right arm-modified Hexon/E3/Fiber sequence and an E1a expression cassette controlled by a left arm tumor-specific promoter, and the difficulties and obstacles to the modification of the adenovirus backbone large vector are overcome. After two rounds of site-specific recombination, the ideal oncolytic adenovirus is packaged accurately and quickly.

Provided are compounds of Formula (II) that enhance the efficacy of viruses by increasing spread of the virus in cells, increasing the titer of virus in cells, or increasing the antigen expression from a virus, gene or trans-gene expression from a virus, or virus protein expression in cells. Other uses, compositions and methods of using same are also provided. ##STR00001##

Herein are reported novel DNA constructs and methods using the same. The current invention uses a deliberate arrangement of non-productive/inactive promoters and genes on coding and template strands of DNA molecules, which are converted into their active form by the interaction with a site-specific recombinase. In more detail, the DNA element according to the current invention is non-functional with respect to the expression of the contained first and second genes. By being non-functional with respect to the expression of the first and second gene, the DNA element according to the invention can be integrated into genome of a cell without the risk that the comprised structural genes are expressed already directly after the integration. The genes are only expressed once a recombinase recognizing and functional with the recombination recognition sequences of the DNA element is activated or introduced into the cell. Thereby, a recombinase mediated cassette inversion (RMCI) between the first and second mutated recombinase recognition sequences in the genomically integrated DNA element of the invention is initiated. The RMCI results in an inversion of that part of the DNA element according to the invention that is located between the two mutant recombinase recognition sequences. Thereby the first promoter becomes operably linked to the first gene and the second promoter becomes operably linked to the second gene. Only thereafter, the first and second genes are transcribed and the respective encoded proteins are expressed. Thus, the DNA element according to the current invention is especially useful in the simultaneous activation of two genes within a cell.

Methods to produce helper dependent adenovirus, and a cell, vector and kit useful in that regard, are provided.